CureVac B.V. (CVAC)

[@LaughinPaulRyan]

... CUREVAC IPO DAY ... $CVAC

MR. MENICHELLA: Thank you, Mr. President, Mr. Vice President. Thanks for having me here. I’m Dan Menichella, CEO of CureVac. We’re a clinical stage biotech company. We use messenger RNA technology, optimize the messenger RNA molecules. Once injected into the body, they instruct the cells on how to make proteins. For instance, we can use the mRNA technology to trigger an immune response against viruses, or we can get the body to increase its production of T-cells for cancer vaccines.

In this way, CureVac can make potent prophylactic vaccines and cancer treatments. The technology also works well to replace missing proteins so we can also work in (inaudible).

One strength of our technology is that we can produce prophylactic vaccines using a very low dose. So, for instance, the phase one rabies trial that we just completed was done at a one-microgram dose, so, in other words, a millionth of a gram dose — a very, very tiny dose.

And so, more broadly, our company focuses — so, this year, we have four programs in phase one clinical trials, and the coronavirus program would be the fifth program in phase one. We expect that the phase one program for coronavirus will start at the beginning of June.

Our technology platform is fast and it’s agile. We were the first messenger RNA company to have GMP manufacturing. We started in 2006. Currently, we have three large-scale GMP facilities, and we are up and running now. Today we have a fourth facility built, and we’re looking for additional capex to put the machinery in there. Once we have that machinery in the fourth building, we can make HUNDREDS OF MILLIONS of doses of the coronavirus vaccine. So we’re very excited about that and we want to help there.

Additionally, we have developed a fully automated production machine. This automated machine if part of the collaboration with CEPI. And additionally, with CEPI, we are working on the coronavirus. They have funded our efforts to get the program and the vaccine to phase one by June.

The key point here being that we believe we can develop the vaccine for COVID-19 very, very quickly, and we have the wherewithal to manufacture it, although we would like some additional help on our largest GMP fourth facility.

Again, we appreciate the opportunity to be here today, and thank you very much.

THE PRESIDENT: Thank you. Thank you very much. Appreciate it. - https://www.whitehouse.gov/briefings-statements/remarks-president-trump-members-coronavirus-task-force-meeting-pharmaceutical-companies/" rel="nofollow" target="_blank" >SOURCE: WHITEHOUSE.GOV